In vivo CAR-T therapy: from molecular design to precision delivery
Abstract In 2017, the United States Food and Drug Administration (FDA) granted the inaugural approval of chimeric antigen receptor T cell (CAR-T) therapy, marking the advent of a new era in cancer immunotherapy. However, the conventional ex vivo CAR‑T cell manufacturing workflow is complex and time...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2026-04-01
|
| シリーズ: | Journal of Nanobiotechnology |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12951-026-04232-5 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|